Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-8.71 Insider Own30.33% Shs Outstand16.93M Perf Week-2.81%
Market Cap169.81M Forward P/E- EPS next Y-3.12 Insider Trans0.00% Shs Float11.80M Perf Month68.29%
Income-30.50M PEG- EPS next Q-0.61 Inst Own25.98% Short Float / Ratio2.16% / 1.46 Perf Quarter25.53%
Sales37.34M P/S4.55 EPS this Y88.38% Inst Trans-8.84% Short Interest0.26M Perf Half Y29.07%
Book/sh1.11 P/B9.08 EPS next Y-31.52% ROA-46.54% Target Price14.10 Perf Year39.19%
Cash/sh1.87 P/C5.37 EPS next 5Y- ROE-284.33% 52W Range3.11 - 33.55 Perf YTD38.21%
Dividend- P/FCF- EPS past 5Y-24.57% ROI-189.78% 52W High-70.10% Beta2.09
Dividend %- Quick Ratio1.89 Sales past 5Y173.00% Gross Margin92.45% 52W Low222.51% ATR1.35
Employees50 Current Ratio1.89 Sales Q/Q-67.33% Oper. Margin-100.14% RSI (14)55.32 Volatility13.38% 15.60%
OptionableNo Debt/Eq3.19 EPS Q/Q87.04% Profit Margin-81.68% Rel Volume1.27 Prev Close10.62
ShortableYes LT Debt/Eq2.54 EarningsNov 09 AMC Payout- Avg Volume175.38K Price10.03
Recom1.57 SMA202.89% SMA5050.42% SMA20040.92% Volume221,026 Change-5.56%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Initiated TD Cowen Outperform
Jul-06-22Resumed Canaccord Genuity Buy $16
Sep-28-21Upgrade Citigroup Neutral → Buy $16
Jun-08-21Downgrade Citigroup Buy → Neutral $25 → $16
Jun-07-21Downgrade Wedbush Outperform → Neutral
May-28-21Initiated Cantor Fitzgerald Overweight $40
May-10-21Initiated Piper Sandler Overweight $35
Dec-23-20Resumed H.C. Wainwright Buy $31
May-22-20Initiated Piper Sandler Overweight $35
Feb-28-20Initiated SunTrust Buy
Dec-05-23 12:00PM
Nov-30-23 11:07AM
Nov-15-23 08:50AM
Nov-14-23 09:55AM
04:01PM Loading…
Nov-09-23 04:01PM
Nov-02-23 09:15AM
Oct-23-23 07:17AM
Oct-21-23 11:31AM
Oct-16-23 04:05PM
Oct-09-23 04:17PM
Sep-28-23 03:00AM
Sep-15-23 07:15AM
Sep-13-23 04:05PM
Sep-06-23 07:30AM
08:05AM Loading…
Sep-05-23 08:05AM
Aug-09-23 05:40PM
Aug-03-23 07:30AM
Aug-01-23 07:30AM
Jul-10-23 09:00AM
Jun-27-23 07:30AM
Jun-26-23 05:14PM
May-28-23 08:24AM
May-11-23 05:55PM
May-09-23 05:25PM
Apr-18-23 01:30PM
Apr-17-23 01:30PM
04:05PM Loading…
Apr-10-23 04:05PM
Apr-01-23 08:40AM
Mar-29-23 06:24AM
Mar-27-23 04:05PM
Mar-14-23 06:21PM
Feb-08-23 07:50AM
Feb-07-23 07:30AM
Feb-02-23 11:28AM
Jan-25-23 08:50AM
Dec-16-22 12:09PM
Dec-12-22 07:37AM
Dec-11-22 10:00AM
Dec-05-22 07:30AM
Nov-21-22 04:59PM
Nov-19-22 07:12AM
Nov-14-22 05:25PM
Nov-03-22 09:09AM
Oct-04-22 07:30AM
Sep-19-22 04:05PM
Sep-01-22 07:30AM
Aug-17-22 06:07AM
Aug-10-22 05:15PM
Aug-02-22 07:30AM
Jul-26-22 07:19AM
Jul-06-22 07:30AM
Jun-27-22 12:50PM
May-26-22 05:00PM
May-14-22 08:20AM
May-12-22 05:25PM
May-04-22 04:06PM
May-02-22 09:00AM
Apr-18-22 10:56AM
Apr-12-22 07:30AM
Apr-07-22 04:05PM
Mar-11-22 10:53AM
Mar-10-22 05:45PM
Mar-08-22 06:55PM
Mar-07-22 07:30AM
Mar-03-22 04:23AM
Mar-02-22 07:30AM
Mar-01-22 10:15AM
Feb-28-22 05:45PM
Feb-09-22 07:30AM
Jan-12-22 10:00AM
Jan-11-22 08:00AM
Dec-13-21 04:05PM
Dec-11-21 09:00AM
Dec-07-21 07:30AM
Nov-12-21 07:00AM
Nov-10-21 06:05PM
Nov-09-21 04:01PM
Nov-04-21 09:00AM
Oct-27-21 03:03PM
Oct-26-21 04:15PM
Oct-05-21 07:30AM
Sep-25-21 09:24AM
Sep-02-21 07:30AM
Aug-13-21 03:04AM
Aug-08-21 07:22PM
Aug-05-21 06:55PM
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUNT RONALDDirectorMar 23Buy1.0010,00010,00010,000Mar 27 05:37 PM